<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" VersionID="2" Owner="NLM">
      <PMID Version="2">35359913</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2666-6065</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Lancet regional health. Western Pacific</Title>
          <ISOAbbreviation>Lancet Reg Health West Pac</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Safety monitoring of COVID-19 vaccines in Japan.</ArticleTitle>
        <Pagination>
          <StartPage>100442</StartPage>
          <MedlinePgn>100442</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">100442</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lanwpc.2022.100442</ELocationID>
        <Abstract>
          <AbstractText>The assessment of the efficacy and safety of coronavirus disease 2019 (COVID-19) vaccines in actual practice is extremely important, and monitoring efforts are being implemented worldwide. In Japan, a joint council in the Ministry of Health, Labour and Welfare is held every two to three weeks to summarise information on the adverse events following COVID-19 vaccination, with careful assessment of individual case safety reports and comparison with background incidence rates. In 2021, the joint council mainly reviewed anaphylaxis, death, myocarditis/pericarditis, and thrombosis with thrombocytopenia syndrome. These activities resulted in several safety-related regulatory actions, including the revision of vaccine package inserts with warnings about myocarditis/pericarditis. International sharing of vaccine safety information, as well as details of the evaluation systems, is important for international discussion and decision-making on better safety monitoring of COVID-19 vaccines.</AbstractText>
          <CopyrightInformation>© 2022 The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yamaguchi</LastName>
            <ForeName>Toshihiro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Immunisation Office, Health Service Division, Health Service Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iwagami</LastName>
            <ForeName>Masao</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Health Services Research, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ishiguro</LastName>
            <ForeName>Chieko</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Clinical Epidemiology, Department of Data Science, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fujii</LastName>
            <ForeName>Daisuke</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Safety Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yamamoto</LastName>
            <ForeName>Norihisa</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Immunisation Office, Health Service Division, Health Service Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Narisawa</LastName>
            <ForeName>Manabu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Immunisation Office, Health Service Division, Health Service Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsuboi</LastName>
            <ForeName>Takashi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Immunisation Office, Health Service Division, Health Service Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Umeda</LastName>
            <ForeName>Hikari</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kinoshita</LastName>
            <ForeName>Natsumi</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iguchi</LastName>
            <ForeName>Toyotaka</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Noda</LastName>
            <ForeName>Tatsuya</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Public Health, Health Management and Policy, Nara Medical University, Nara, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsuruta</LastName>
            <ForeName>Shinya</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Immunisation Office, Health Service Division, Health Service Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oka</LastName>
            <ForeName>Akira</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Saitama Children's Medical Center, Saitama, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morio</LastName>
            <ForeName>Tomohiro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakai</LastName>
            <ForeName>Kiyohito</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Safety Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hayashi</LastName>
            <ForeName>Shuichiro</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Immunisation Office, Health Service Division, Health Service Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Lancet Reg Health West Pac</MedlineTA>
        <NlmUniqueID>101774968</NlmUniqueID>
        <ISSNLinking>2666-6065</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">Epidemiology</Keyword>
        <Keyword MajorTopicYN="N">Health policy</Keyword>
        <Keyword MajorTopicYN="N">Pharmacovigilance</Keyword>
        <Keyword MajorTopicYN="N">Vaccines</Keyword>
      </KeywordList>
      <CoiStatement>AO receives grants from Eisai Co., Ltd, SHIONOGI &amp; CO., LTD., Takeda Pharmaceutical Co, Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., and Pfizer Japan Inc. All other authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>5</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35359913</ArticleId>
        <ArticleId IdType="pmc">PMC8960038</ArticleId>
        <ArticleId IdType="doi">10.1016/j.lanwpc.2022.100442</ArticleId>
        <ArticleId IdType="pii">S2666-6065(22)00057-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>WHO Coronavirus disease (COVID-19) dashboard; 2020. https://covid19.who.int/. Accessed 10 January 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Ritchie H, Mathieu E, Rodés-Guirao L, et al. Coronavirus Pandemic (COVID-19); 2020. published online March 5. https://ourworldindata.org/covid-vaccinations?country=JPN. Accessed 10 January 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Ministry of Health, Labour and Welfare. Revision of Precautions. Coronavirus modified uridine RNA vaccine (SARS-CoV-2) (Comirnaty intramuscular injection); 2021. https://www.pmda.go.jp/files/000243865.pdf. Accessed 10 January 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Ministry of Health, Labour and Welfare. Revision of Precautions. Coronavirus modified uridine RNA vaccine (SARS-CoV-2) (COVID-19 Vaccine Moderna Intramuscular Injection); 2021. https://www.pmda.go.jp/files/000243866.pdf. Accessed 10 January 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Ministry of Health, Labour and Welfare. Health Sciences Council (the Immunization and Vaccination committee - the committee on Adverse Reactions) [in Japanese]. https://www.mhlw.go.jp/stf/shingi/shingi-kousei_284075.html. Accessed 4 March 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Immunization Act (Act No. 68 of 1948) (Amendment Act No. 75 of 2020). [in Japanese] https://elaws.e-gov.go.jp/document?lawid=323AC0000000068&amp;msclkid=54af0d94a93211ec8ff6f73a9b87d507. Accessed 22 March 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Act on securing quality, efficacy and safety of products including pharmaceuticals and medical devices (Act No. 145 of 1960) (Amendment Act No. 63 of 2019). [in Japanese] https://elaws.e-gov.go.jp/document?lawid=335AC0000000145_20210801_501AC0000000063&amp;keyword=%E8%96%AC%E6%A9%9F%E6%B3%95. Accessed 22 March 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Report of Suspected Adverse Reactions after Immunization (Attachment Form 1) [in Japanese]. https://www.pmda.go.jp/safety/reports/hcp/prev-vacc-act/0002.html. Accessed 10 January 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Organization. Reporting form for adverse event following immnization (AEFI). https://www.who.int/vaccine_safety/initiative/tools/AEFI_reporting_form_EN_Jan2016.pdf. Accessed 4 March 2022</Citation>
        </Reference>
        <Reference>
          <Citation>ICH E2B (R3) Electronic transmission of individual case safety reports (ICSRs) - data elements and message specification - implementation guide; 2013. https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-4.pdf. Accessed 10 January 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Pharmaceuticals and Medical Devices Agency Act (Act No. 192 of 2002) (Amendment Act No. 63 in 2019) [in Japanese]. https://elaws.e-gov.go.jp/document?lawid=414AC0000000192. Accessed 10 January 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Pharmaceuticals and Medical Devices Agency. Terms and Conditions for Japanese adverse drug event report database (JADER) [in Japanese]; 2015. https://www.pmda.go.jp/safety/info-services/drugs/adr-info/suspected-adr/0003.html. Accessed 10 January 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Japanese Government Chief Information Officers’ Portal. Vaccination Record System (VRS) [in Japanese]; 2021. published online Jan 25. https://cio.go.jp/vrs. Accessed 10 January 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Ministry of Health, Labour and Welfare. Overview of vital statistics (fixed number) in the first year of Reiwa (2019) [in Japanese]; 2020. published online Sept 17. https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei19/index.html. Accessed 10 January 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Yasunaga H. Real world data in Japan: chapter I NDB. Ann of Clin Epidemiol. 2019;1:28–30.</Citation>
        </Reference>
        <Reference>
          <Citation>Uppsala Monitoring Centre. What is a signal? https://who-umc.org/signal-work/what-is-a-signal/. Accessed 4 March 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Brighton Collaboration Case Definitions; 2021. https://brightoncollaboration.us/category/pubs-tools/case-definitions/. Accessed 10 January 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Klein N. Rapid cycle analysis to monitor the safety of COVID-19 vaccines in near real-time within the vaccine safety datalink: myocarditis and anaphylaxis; 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-08-30/04-COVID-Klein-508.pdf. Accessed 10 January 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Medicines and Healthcare products Regulatory Agency. Coronavirus (COVID-19) vaccines adverse reactions; 2021. https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions. Accessed 11 January 2022).</Citation>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention. Selected adverse events reported after COVID-19 vaccination; 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html. Accessed 10 January 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Pottegård A., Lund L.C., Karlstad Ø., et al.  Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373:n1114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8097496</ArticleId>
            <ArticleId IdType="pubmed">33952445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez Bernal J., Andrews N., Gower C., et al.  Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on Covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:n1088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8116636</ArticleId>
            <ArticleId IdType="pubmed">33985964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein N.P., Lewis N., Goddard K., et al.  Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326:1390–1399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8511971</ArticleId>
            <ArticleId IdType="pubmed">34477808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witberg G., Barda N., Hoss S., et al.  Myocarditis after COVID-19 vaccination in a large health care organization. N Engl J Med. 2021;385:2132–2139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8531986</ArticleId>
            <ArticleId IdType="pubmed">34614329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mevorach D., Anis E., Cedar N., et al.  Myocarditis after BNT162b2 mRNA vaccine against COVID-19 in Israel. N Engl J Med. 2021;385:2140–2149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8531987</ArticleId>
            <ArticleId IdType="pubmed">34614328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simone A., Herald J., Chen A., et al.  Acute myocarditis following COVID-19 mRNA vaccination in adults aged 18 years or older. JAMA Intern Med. 2021;181:1668–1670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8491129</ArticleId>
            <ArticleId IdType="pubmed">34605853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barda N., Dagan N., Ben-Shlomo Y., et al.  Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. N Engl J Med. 2021;385:1078–1090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8427535</ArticleId>
            <ArticleId IdType="pubmed">34432976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention. Vaccines and Immunizations. Myocarditis and pericarditis considerations; 2021. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html. Accessed 10 January 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Ministry of Health, Labour and Welfare. Revision of Precautions, coronavirus modified uridine RNA vaccine; 2021. https://www.pmda.go.jp/files/000241562.pdf. Accessed 10 January 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency. Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]) – COVID-19 Vaccine AstraZeneca (Other viral vaccines); 2021. https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant-covid_en.pdf. Accessed 10 January 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Weintraub MPH, Fireman B, Gee J, et al. Rapid Cycle Analysis (RCA) to monitor the safety of COVID-19 vaccines in near real-time within the Vaccine Safety Datalink. 2021. https://www.cdc.gov/vaccinesafety/pdf/VSD-1342-COVID19-RCA-Protocol_FinalV1.1_508.pdf. Accessed 10 January 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Hippisley-Cox J., Patone M., Mei X.W., et al.  Risk of thrombocytopenia and thromboembolism after COVID-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ. 2021;374:n1931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8388189</ArticleId>
            <ArticleId IdType="pubmed">34446426</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
